PositiveID Corporation Appoints Lyle L. Probst President
April 21 2014 - 8:30AM
PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a
developer of biological detection and diagnostics solutions,
announced today that it has appointed Lyle L. Probst President of
the Company. Mr. Probst, who has 15 years of managerial experience
with large bio-detection programs and products, joined PositiveID
in 2011 at the time that PositiveID acquired Microfluidic Systems,
based in Pleasanton, CA.
Before joining Microfluidic Systems, Mr. Probst directed
bio-detection programs at Lawrence Livermore National Laboratory
("LLNL"). He managed a series of bio-detection programs such as the
Department of Homeland Security Science & Technology BAND
(Bioagent Autonomous Networked Detector) program, and the
development and deployment of BioWatch Generation 1 laboratory at
LLNL, and was principal investigator/developer of the
high-throughput BioWatch mobile laboratory at LLNL as an employee
of SAIC. Mr. Probst was previously the Director of Capillary
Electrophoresis and Director of Chemistries at the Joint Genome
Institute. He holds a B.S. in Biology and an M.B.A in Executive
Management.
"Over the past three years, our team has accomplished several
significant milestones, including teaming with major government
contractors, receiving a $2.5 million license fee from a large
partner, and last month entering into a strategic contract to
demonstrate our M-BAND product in a Defense Department program,"
Probst stated. "I am confident that our best-in-class technology,
partners, and capabilities position us well for success."
William J. Caragol, Chairman and CEO of PositiveID, said,
"Lyle's performance and results speak for themselves. I am proud of
what Lyle and the team have achieved and we are eager to reach the
major goals we've set for 2014 and beyond."
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and
developer of biological detection systems for America's homeland
defense industry as well as rapid biological testing. PositiveID is
focused on the development of microfluidic systems for the
automated preparation of and performance of biological assays in
order to detect biological threats and analyze biological samples.
For more information on PositiveID, please visit
http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations including,
without limitation, the likelihood that the Company's best-in-class
technology, partners, and capabilities position it well for
success, constitute "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the
Private Litigation Reform Act of 1995. Such forward-looking
statements involve risks and uncertainties and are subject to
change at any time, and PositiveID's actual results could differ
materially from expected results. Additional information about
these and other factors that could affect the Company's business is
set forth in the Company's various filings with the Securities and
Exchange Commission, including those set forth in the Company's
10-K filed on April 11, 2014, and 10-Qs filed on May 20, 2013,
August 14, 2013, as amended August 19, 2013, and November 19, 2013,
under the caption "Risk Factors." The Company undertakes no
obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after
the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
CONTACT: PositiveID Corporation
Allison Tomek
561-805-8000
atomek@positiveidcorp.com